圣诺医药-B(02257)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02257 圣诺医药-B

收市竞价 08-18 16:09:27

4.095

-0.105

-2.50%

最高4.345	最低4.090	成交量2.65万
今开4.150	昨收4.200	日振幅6.07%
总市值4.59亿	流通市值4.59亿	总股本1.12亿
成交额11.04万	换手率0.02%	流通股本1.12亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02257","market":"HK","secType":"STK","nameCN":"圣诺医药-B","latestPrice":4.095,"timestamp":1787040483263,"preClose":4.2,"halted":0,"volume":26500,"delay":0,"changeRate":-0.025000000000000102,"floatShares":112000000,"shares":112000000,"eps":-0.152476,"marketStatus":"收市竞价","change":-0.105,"latestTime":"08-18 16:09:27","open":4.15,"high":4.345,"low":4.09,"amount":110378,"amplitude":0.060714,"askPrice":4.095,"askSize":47850,"bidPrice":4,"bidSize":7600,"shortable":0,"etf":0,"ttmEps":-0.999,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1787040600000},"marketStatusCode":4,"adr":0,"listingDate":1640793600000,"exchange":"SEHK","adjPreClose":4.2,"openAndCloseTimeList":[[1787016600000,1787025600000],[1787029200000,1787040000000]],"volumeRatio":0.602958,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02257","defaultTab":"news","newsList":[{"id":"2660105127","title":"因2000万美元投资暴雷，圣诺医药将创始人等前高管告上法庭","url":"https://stock-news.laohu8.com/highlight/detail?id=2660105127","media":"深圳商报·读创","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660105127?lang=zh_cn&edition=full","pubTime":"2026-08-17 08:15","pubTimestamp":1786925742,"startTime":"0","endTime":"0","summary":"港股圣诺医药近日公告称，公司及其直接全资附属公司圣诺（香港）有限公司8月14日向香港特别行政区高等法院提交传讯令状，正式起诉其创始人陆阳及另外两名前管理层戴晓畅、叶永基。圣诺医药今年股价走势疲弱，至今大跌45%。此次起诉与一笔约2000万美元的投资有关。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608173842621864.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608173842621864.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","02257"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659203281","title":"2000万美元投资亏损，“小核酸第一股”起诉创始人陆阳","url":"https://stock-news.laohu8.com/highlight/detail?id=2659203281","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659203281?lang=zh_cn&edition=full","pubTime":"2026-08-15 11:34","pubTimestamp":1786764840,"startTime":"0","endTime":"0","summary":"因为一笔投资亏损，“小核酸第一股”将创始人告上了法庭。8月14日，圣诺医药（2257.HK）发布公告称，公司及其直接全资附属公司圣诺（香港）有限公司已向香港特别行政区高等法院提交传讯令状，控告集团若干前管理层，包括陆阳、戴晓畅及叶永基。圣诺医药称，公司已指示其法律顾问采取一切必要措施，以维护本集团的合法权益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608153842392995.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608153842392995.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02257","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191720128","title":"圣诺医药-B（02257）向香港高院提出诉讼　追责前管理层涉约2,000万美元投资","url":"https://stock-news.laohu8.com/highlight/detail?id=1191720128","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191720128?lang=zh_cn&edition=full","pubTime":"2026-08-14 21:06","pubTimestamp":1786712793,"startTime":"0","endTime":"0","summary":"2026年8月14日，圣诺医药-B发布内幕消息公告称，公司及其全资子公司圣诺（香港）有限公司已向香港特别行政区高等法院提交传讯令状，被告为公司若干前管理层成员陆阳博士、戴晓畅博士及叶永基先生。诉讼涉及集团此前对TradArt Flagship Investment SPC独立投资组合作出的本金总额约2,000万美元投资。圣诺医药-B提醒股东及潜在投资者在买卖公司股份时保持审慎。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02257"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659513144","title":"圣诺医药-B(02257.HK)已向法院提交传讯令状，控告集团若干前管理层，包括陆阳、戴晓畅及叶永基","url":"https://stock-news.laohu8.com/highlight/detail?id=2659513144","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659513144?lang=zh_cn&edition=full","pubTime":"2026-08-14 21:05","pubTimestamp":1786712723,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02257"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172328393","title":"圣诺医药-B将于8月28日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1172328393","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172328393?lang=zh_cn&edition=full","pubTime":"2026-08-14 17:06","pubTimestamp":1786698365,"startTime":"0","endTime":"0","summary":"圣诺医药-B（02257）8月14日发布公告称，公司董事会已排期于2026年8月28日（星期五）召开会议，审议并批准公司及其附属公司截至2026年6月30日止六个月的中期业绩及其发布事宜。\n公告显示，会议由董事会主席兼执行董事潘洪辉博士主持。\n截至公告披露日，董事会成员包括执行董事潘洪辉博士；非执行董事殷惠军博士；以及独立非执行董事王宇山先生、张鹏博士及卢懿杏女士。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02257"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153646416","title":"圣诺医药-B(02257)完成一般授权新股认购 募资约11.3百万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1153646416","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153646416?lang=zh_cn&edition=full","pubTime":"2026-08-12 17:06","pubTimestamp":1786525594,"startTime":"0","endTime":"0","summary":"2026年8月12日，圣诺医药-B公告称，公司根据先前于2026年5月23日及6月1日披露的认购协议，已于2026年8月12日完成新股认购交易。– 本次共配发及发行2,435,600股新股份，约占完成后已发行股份总数的2.17%。– 认购价为每股4.69港元。– 认购事项净筹约11.3百万元，拟全部用于集团一般营运资金。– 完成前，公司已发行股份为109,721,538股；完成后增至112,157,138股。公司表示，本次募得资金将增强流动性，支持其日常运营。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02257"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190661563","title":"圣诺医药-B：8月12日发行243.56万股新股，涉资约1,142.30万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1190661563","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190661563?lang=zh_cn&edition=full","pubTime":"2026-08-12 17:05","pubTimestamp":1786525558,"startTime":"0","endTime":"0","summary":"圣诺医药-B（股票代码：02257）于2026年8月12日发布翌日披露报表，宣布依据2026年5月23日签署的认购协议，并根据一般授权完成新股份发行。此次增发股票数量为2,435,600股，约占发行前公司已发行股本的2.22%；增发价格为每股4.69港元，合计涉资约1,142.30万港元。\n本次发行完成后，圣诺医药-B已发行股本增至112,157,138股，库藏股数为0股。公司在公告中确认，相关股份发行已获得董事会批准，并遵守了适用上市规则及相关法律规定。该公告由公司秘书袁润廷签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"圣诺医药-B：8月12日发行243.56万股新股，涉资约1,142.30万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02257"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658161978","title":"圣诺医药-B(02257)完成发行合共243.56万股认购股份 净筹约1130万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2658161978","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658161978?lang=zh_cn&edition=full","pubTime":"2026-08-12 17:01","pubTimestamp":1786525301,"startTime":"0","endTime":"0","summary":"智通财经APP讯，圣诺医药-B(02257)发布公告，认购协议的所有先决条件均已达成，而认购事项已于2026年8月12日完成。合共243.56万股认购股份(占紧随完成后已发行股份数目约2.17%)已根据认购协议的条款及条件，按认购价每股认购股份4.69港元配发及发行予认购人。认购事项所得款项净额约为1130万港元。本集团拟将认购事项所得款项用作其一般营运资金。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479000.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"圣诺医药-B(02257)完成发行合共243.56万股认购股份 净筹约1130万港元","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02257","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168755364","title":"圣诺医药-B7月股份变动月报：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1168755364","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168755364?lang=zh_cn&edition=full","pubTime":"2026-08-05 17:47","pubTimestamp":1785923259,"startTime":"0","endTime":"0","summary":"圣诺医药-B于2026年8月5日发布截至2026年7月31日的股份变动月报表。公告显示，公司在本期内已发行股份、注册股本及库藏股份规模均未发生变化。在期权与股权激励方面，2022年购股权计划期末结存110,199份，同比上月底减少609,641份失效期权；本月内未有期权被授出或行使。2026年购股权计划暂无实质行权变化，本月亦无授出或行使记录，但预留可发行上限共计10,972,153份购股权。截至2026年7月31日，公司整体股权结构维持稳定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02257"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174608009","title":"圣诺医药-B宣布STP 705医美II期临床试验完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1174608009","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174608009?lang=zh_cn&edition=full","pubTime":"2026-07-30 17:26","pubTimestamp":1785403591,"startTime":"0","endTime":"0","summary":"圣诺医药-B2026年7月30日发布自愿性公告称，其RNA疗法管线项目STP 705用于医美适应症的II期多中心临床试验已完成首名研究参与者首次给药，这是该项目的重要临床里程碑。该II期试验的主要终点为系统性评估STP 705通过局部给药实现靶向皮下脂肪减少的临床疗效；次要评估涵盖安全性、耐受性及局部治疗反应特征。公司在公告中提醒，当前无法保证能够成功开发或最终将STP 705商业化。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02257"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655982201","title":"圣诺医药-B(02257.HK)：STP705用于医疗美容的II期临床试验完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2655982201","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655982201?lang=zh_cn&edition=full","pubTime":"2026-07-30 17:18","pubTimestamp":1785403092,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02257","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164972885","title":"圣诺医药-B（02257.HK）设立外部科学顾问委员会 加强RNAi疗法研发布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1164972885","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164972885?lang=zh_cn&edition=full","pubTime":"2026-07-21 17:05","pubTimestamp":1784624733,"startTime":"0","endTime":"0","summary":"2026年7月21日，圣诺医药-B发布自愿性公告称，已正式成立外部科学顾问委员会，以就集团治疗管线研发项目提供独立且权威的科学指导。新成立的科学顾问委员会由五名跨学科国际专家组成，覆盖RNA递送技术、RNA干扰药物发现、肿瘤学研发、临床转化医学、化学—制造—控制及全球药品监管合规等领域。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02257"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653278381","title":"圣诺医药-B(02257)成立外部科学顾问委员会","url":"https://stock-news.laohu8.com/highlight/detail?id=2653278381","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653278381?lang=zh_cn&edition=full","pubTime":"2026-07-21 17:01","pubTimestamp":1784624473,"startTime":"0","endTime":"0","summary":"智通财经APP讯，圣诺医药-B(02257)发布公告，于2026年7月21日，本公司成立外部科学顾问委员会(科学顾问委员会)，以为本集团的治疗管线研发项目提供独立、权威的科学指导。科学顾问委员会由五名国际知名的跨学科专家组成，彼等在RNA递送技术、RNAi药物发现、肿瘤学研究与开发(研发)、临床转化医学、化学、制造与控制(CMC)活动以及全球药品监管合规方面拥有深厚的专业知识。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1470356.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02257","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188633451","title":"圣诺医药-B六月股份月报：股本维持稳定 无新增发行或回购","url":"https://stock-news.laohu8.com/highlight/detail?id=1188633451","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188633451?lang=zh_cn&edition=full","pubTime":"2026-07-06 19:51","pubTimestamp":1783338665,"startTime":"0","endTime":"0","summary":"圣诺医药-B于2026年7月6日披露截至2026年6月30日止的股份变动月报表。根据公告，公司本月无新增股份发行、购回及库存股变动，股本结构维持稳定。公司“2022年受限制股份单位计划”允许发行最多8,904,023股，截至本月末并未出现新股发行。公司表示，截至2026年6月30日，已满足香港联交所相关的公众持股量要求。公司同时确认本月所有证券发行及（如有）股份转让均已符合香港联交所《上市规则》等相关法律法规的规定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02257"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645181533","title":"圣诺医药-B(02257.HK)获主席潘洪辉增持2.03万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645181533","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645181533?lang=zh_cn&edition=full","pubTime":"2026-06-24 21:06","pubTimestamp":1782306392,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02257"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641162191","title":"圣诺医药-B(02257)：欧阳云龙辞任非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2641162191","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2641162191?lang=zh_cn&edition=full","pubTime":"2026-06-05 17:02","pubTimestamp":1780650141,"startTime":"0","endTime":"0","summary":"智通财经APP讯，圣诺医药-B(02257)发布公告，董事会已接获欧阳云龙先生(欧阳先生)提交辞任函，辞任本公司非执行董事、董事会辖下审核委员会成员及薪酬委员会成员，自2026年6月5日起生效，原因为欧阳先生希望投放更多时间于彼其他事务上。自2026年6月5日起，非执行董事殷惠军博士获委任为审核委员会及薪酬委员会成员。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450720.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"圣诺医药-B(02257)：欧阳云龙辞任非执行董事","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02257"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184107714","title":"圣诺医药-B公布5月股份变动月报表 股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1184107714","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184107714?lang=zh_cn&edition=full","pubTime":"2026-06-03 18:51","pubTimestamp":1780483862,"startTime":"0","endTime":"0","summary":"圣诺医药-B于2026年6月3日发布截至2026年5月31日止月份的证券变动月报表。报告显示，公司法定股本及已发行股份在报告期内均未发生变化，股本保持稳定。公司报告期末法定股本总额为230,000美元，对应230,000,000股普通股，每股面值0.001美元。5月期末已发行普通股总数为109,721,538股，库存股份数量为0股，较上月底均无变动。公司确认已满足相关公众持股量要求。本次月报由公司秘书袁润廷签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02257"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106529545","title":"圣诺医药-B拟回购最多10%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1106529545","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106529545?lang=zh_cn&edition=full","pubTime":"2026-05-28 18:16","pubTimestamp":1779963391,"startTime":"0","endTime":"0","summary":"圣诺医药-B于最新公告披露，董事会已就公司股份回购计划向股东大会提出一般性授权，允许在合资格期间内从公开市场购回不超过公司已发行股本10%的股份。根据公告，截至最后实际可行日期，圣诺医药-B已发行股本为109,721,538股，拟回购上限约10,972,153股。该回购授权将自股东大会通过日起，直至下届股东周年大会结束或有关期限届满时终止。根据公司披露，圣诺医药-B在过去12个月内，股价曾最高达到每股22.78港元，最低为每股2.92港元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"圣诺医药-B拟回购最多10%股份","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02257"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638537928","title":"圣诺医药-B(02257)拟折让约15.34%发行243.56万股 净筹约1130万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2638537928","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638537928?lang=zh_cn&edition=full","pubTime":"2026-05-25 19:19","pubTimestamp":1779707943,"startTime":"0","endTime":"0","summary":"智通财经APP讯，圣诺医药-B(02257)发布公告，于2026年5月23日，公司(作为发行人)拟向认购人(集团企业管理部副总裁谢硕豪先生)发行243.56万股认购股份，相当于于本公告日期公司现有已发行股本约2.22%;及经配发及发行所有认购股份扩大的公司已发行股本约2.17%。认购价每股认购股份4.69港元，较5月22日收市价每股5.54港元折让约15.34%。认购事项所得款项总额将约为1140万港元。认购事项所得款项净额将约为1130万港元。集团拟将认购事项所得款项用作其一般营运资金。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445663.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02257"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114307579","title":"圣诺医药-B4月股份变动月报：股本及已发行股份维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1114307579","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114307579?lang=zh_cn&edition=full","pubTime":"2026-05-06 17:08","pubTimestamp":1778058505,"startTime":"0","endTime":"0","summary":"圣诺医药-B于2026年5月6日披露4月股份变动月报表，报告期为截至2026年4月30日。已发行股份则维持在109,721,538股，库藏股数量为0股，报告期内无新增发行、无股份购回及注销活动。另据公告，公司于2022年4月22日采纳的受限制股份单位计划可发行最多8,904,023股，报告期内同样未有新增发股或从库藏股转让，年度特別授权所涉2,671,206股的有效期已于2026年4月30日届满。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02257"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"https://www.sirnaomics.com/en/","stockEarnings":[{"period":"1week","weight":0.0579},{"period":"1month","weight":-0.0625},{"period":"3month","weight":-0.3023},{"period":"6month","weight":-0.4247},{"period":"1year","weight":-0.5364},{"period":"ytd","weight":-0.4524}],"compareEarnings":[{"period":"1week","weight":-0.0187},{"period":"1month","weight":0.0363},{"period":"3month","weight":-0.0134},{"period":"6month","weight":-0.0469},{"period":"1year","weight":0.0072},{"period":"ytd","weight":-0.0069}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"Sirnaomics Ltd是一家投资控股公司。该公司及其子公司均为临床阶段生物技术公司，致力于开发和商业化核糖核酸干扰（RNAi）技术及多种疗法。该公司专注于发现和开发针对特定领域尚未满足医疗需求的药物。该公司主要临床候选药物包括STP705和STP707。STP705是一种多靶点siRNA疗法，目前正在推进针对两种肿瘤适应症的临床开发：原位鳞状细胞癌（isSCC）和基底细胞癌（BCC）。STP707是一种静脉注射siRNA疗法，目前正在进行针对多种实体瘤（包括结直肠癌、胰腺癌、肝癌和转移性黑色素瘤）的I期临床试验。该公司正充分利用其双重递送平台，包括多肽纳米颗粒（PNP）和GalAhead。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.131369},{"month":2,"riseRate":0.6,"avgChangeRate":-0.02454},{"month":3,"riseRate":0.2,"avgChangeRate":-0.124827},{"month":4,"riseRate":0.4,"avgChangeRate":-0.031494},{"month":5,"riseRate":0.4,"avgChangeRate":0.01256},{"month":6,"riseRate":0.6,"avgChangeRate":-0.050821},{"month":7,"riseRate":0.6,"avgChangeRate":0.098945},{"month":8,"riseRate":0.4,"avgChangeRate":-0.056592},{"month":9,"riseRate":0.75,"avgChangeRate":0.238751},{"month":10,"riseRate":0,"avgChangeRate":-0.180246},{"month":11,"riseRate":0,"avgChangeRate":-0.082953},{"month":12,"riseRate":0.5,"avgChangeRate":0.008221}],"exchange":"SEHK","name":"圣诺医药-B","nameEN":"SIRNAOMICS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"圣诺医药-B(02257)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供圣诺医药-B(02257)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"圣诺医药-B,02257,圣诺医药-B股票,圣诺医药-B股票老虎,圣诺医药-B股票老虎国际,圣诺医药-B行情,圣诺医药-B股票行情,圣诺医药-B股价,圣诺医药-B股市,圣诺医药-B股票价格,圣诺医药-B股票交易,圣诺医药-B股票购买,圣诺医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"圣诺医药-B(02257)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供圣诺医药-B(02257)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}